We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West is now celebrating the one-year anniversary of its Integrated Solutions initiative, known as Simplify the Journey™. Throughout 2019, we socialized the program through marketing materials and face-to-face conversations with customers. Now it’s time to reflect on the lessons we’ve learned — and to look forward to the opportunities on the horizon.
As injectable medicines have evolved, customers have expressed a need for partners that can offer a more holistic approach encompassing the entire lifecycle of an injectable medicine, from early clinical development to commercialization. The Integrated Solutions initiative from West, now celebrating its one-year anniversary, does exactly that, bringing together West’s primary packaging, device, analytical, regulatory and contract manufacturing expertise in a single-source solution.
A New Approach for All Customers
The Integrated Solutions initiative elevates West’s role as a partner and collaborator. Our goal is to complement, not duplicate, the functional capabilities of our customers. This enables them to focus on their core competencies while relying on West for services they may not have or plan to have inhouse. As such, with Integrated Solutions in place, we can offer something to every customer, regardless of their size or where their products sit in the development lifecycle.
According to Jennifer Riter, Senior Director, Analytical Services, “We always knew smaller pharma companies could benefit from this type of bundled solution because they simply don’t have the internal resources to accommodate the full range of services West offers. But we were excited to learn how many larger companies were willing, even eager, to engage us in conversations about how we could help.”
The willingness of customers to engage about an Integrated Solutions approach is directly related to the changes and challenges taking place across the industry. “There are a number of trends driving drug and device manufacturing,” Riter points out. “The continued focus on combination products, as well as many pipelines containing complex molecules, are just a few examples.” As companies struggle to respond to these drivers, they face gaps in experience and knowledge. “Integrated Solutions affords West the opportunity to fill these gaps, to leverage the expertise we’ve acquired over nearly 100 years of manufacturing containers, closures and delivery devices for injectable medicines.”
The Journey Continues
Integrated Solutions is a year old, but in reality, West has been offering many of these services independently to customers for over 20 years. Formalizing the name and providing more structure to the program allows us to truly share with our customers what we have learned and how this knowledge can help address our customer’s needs and challenges.
Looking forward, Integrated Solutions will continue to evolve based on industry needs and challenges. As it does, one thing is certain: West is committed to the program because an integrated, comprehensive approach is required for the rapidly changing pharmaceutical landscape.
As Riter points out, “Ultimately, Integrated Solutions is about bringing together the right drugs, devices, and services needed to ensure the best overall patient experience. But the complexities involved to deliver that ultimate experience are significant. It takes collaboration — between manufacturers and external providers like West — and an interconnected suite of services to ensure a product makes it to the market and is used by the people who need it.”
Simplify the Journey™ is a trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
For the past 10 years, Janet Cooper, Manager, Admin Services, Exton, has done it all at Canine Partners for Life: from cuddling puppies in the kennel, to giving demonstrations, to serving on the Board of Directors.
In August 2022 the European Union revised its guidelines for sterile medicinal products for human and veterinary use. These guidelines came into effect on August 25, 2023. West has compiled the most frequently asked questions about Annex 1 and how it affects sterile drug manufacturers, which will be published across a multi-part series.
Subvisible particulates (defined as those in the 0.1-10 micron range) are a growing concern for injectable drug manufacturers. The particles may cause aggregation, which can impact the drug product and create a potential safety risk for the patient. To help ensure product quality, the U.S. Food and Drug Administration recommends that manufacturers gain a better understanding of how subvisible particles impact the drug.
Here at West, we are working by the side of our patients and customers to help contribute to a healthier world. Meet one of our team members, Rusli Kartadinata, and read his story to learn how he grew in his career at West from a Production Engineer to his current role as the Associate Quality Manager across Asia Pacific.
Cancer affects all of us, whether we are a patient, a family member, a friend, or a colleague of someone fighting cancer. Working together, we can increase our understanding of this disease and support the groundbreaking research that is ongoing in the fight against cancer.
English
Chinese
